Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics

References

• Maini R, St Clair EW, Breedveld F, et al.; for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-39
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al.; for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corp; 2010
   Google Scholar
• Humira (adalimumab injection, solution) [prescribing information]. North Chicago, IL: Abbott Laboratories; 2010
   Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009;36:898-906
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
   PubMed Web of Science ®Google Scholar
• Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64(Suppl 4):iv18-23
   PubMedGoogle Scholar
• Furfaro N, Dewing K, Carlone J, et al. Nurse and physician differences in perception of patient knowledge and approach to education in the treatment of rheumatoid arthritis. Abstract presented at: American College of Rheumatology 2008 Annual Scientific Meeting; October 24-29, 2008; San Francisco, CA. Available at: http://acr.confex.com/acr/2008/webprogram/Paper2043.html [Last accessed 13 May 2010]
   Google Scholar
• New study highlights need for better interaction and education between rheumatoid arthritis patients and care providers [Reuters website]. October 28, 2008. Available at: http://www.reuters.com/article/pressRelease/idUS140818+28-Oct-2008+PRN20081028 [Last accessed 13 May 2010]
   Google Scholar
• Jolly H, Simpson K, Bishop B, et al. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. J Neurosci Nurs 2008;40:232-9
   PubMed Web of Science ®Google Scholar
• Katona C, Peveler R, Dowrick C, et al. Pain symptoms in depression: definition and clinical significance. Clin Med 2005;5:390-95
   PubMed Web of Science ®Google Scholar
• Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61:1922-30
   PubMed Web of Science ®Google Scholar
• Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008;71(Suppl 3):S21-3
   PubMedGoogle Scholar
• Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast cells. Abstract presented at: American College of Rheumatology 2009 Annual Scientific Meeting; October 17-21, 2009; Philadelphia, PA. Available at: http://acr.confex.com/acr/2009/webprogram/Paper13684.html [Last accessed 13 May 2010]
   Google Scholar
• CIMZIA (certolizumab pegol) [prescribing information]. Smyrna, GA: UCB, Inc; 2010
   Google Scholar
• Kimberlin CL, Winterstein AG. Validity and reliability of measurement instruments used in research. Am J Health Syst Pharm 2008;65:2276-84
   PubMed Web of Science ®Google Scholar
• Worster A, Haines T. Advanced statistics: understanding medical record review (MRR) studies. Acad Emerg Med 2004;11:187-92
   PubMed Web of Science ®Google Scholar
• Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83
   PubMed Web of Science ®Google Scholar